Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc finger protein 729 is a member of the C2H2-type zinc finger transcription factor family, predicted to enable sequence-specific DNA binding and transcriptional activation, especially for genes regulated by RNA polymerase II[1][5][6]. It is predominantly localized in the cell nucleus, where it may contribute to transcriptional regulation. While the biological role of ZNF729 is inferred from its structural classification and predicted activity, there is currently no direct evidence linking ZNF729 to well-characterized disease mechanisms, therapeutic interventions, or druggability. Its closest biological relatives and paralogs, such as ZNF99, share similar putative roles in gene expression modulation. More research is needed to define its precise functional impact[5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Zinc finger protein 729 (ZNF729).